Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live vir...
Saved in:
| Published in | PloS one Vol. 17; no. 1; p. e0262657 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
18.01.2022
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses.
Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months.
A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. |
|---|---|
| AbstractList | Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses. Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC.sub.50 results were observed (r.sub.s = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months. A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses.BACKGROUNDTests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses.Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months.METHODS AND RESULTSConfiguration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months.A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots.CONCLUSIONSA competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses. Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months. A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. Background Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses. Methods and results Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC.sub.50 results were observed (r.sub.s = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months. Conclusions A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. Background Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein’s receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses. Methods and results Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months. Conclusions A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. BackgroundTests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein's receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses.Methods and resultsConfiguration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months.ConclusionsA competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. Background Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein’s receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses. Methods and results Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N = 32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs = .83, p < 0.0001). When the competitive ELISA was used to evaluate N = 42 vaccinated individuals and an additional N = 13 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months. Conclusions A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots. |
| Audience | Academic |
| Author | Cantley, Linda Campillo Luna, Julian Lucas, Carolina Klein, Jon Wisnewski, Adam V. Liu, Jian Slade, Martin Redlich, Carrie A. Fazen, Louis Iwasaki, Akiko |
| AuthorAffiliation | Instituto Butantan, BRAZIL 2 Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America 1 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America 3 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America |
| AuthorAffiliation_xml | – name: Instituto Butantan, BRAZIL – name: 2 Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America – name: 3 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America – name: 1 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America |
| Author_xml | – sequence: 1 givenname: Adam V. orcidid: 0000-0003-2461-9409 surname: Wisnewski fullname: Wisnewski, Adam V. – sequence: 2 givenname: Jian surname: Liu fullname: Liu, Jian – sequence: 3 givenname: Carolina surname: Lucas fullname: Lucas, Carolina – sequence: 4 givenname: Jon surname: Klein fullname: Klein, Jon – sequence: 5 givenname: Akiko orcidid: 0000-0002-7824-9856 surname: Iwasaki fullname: Iwasaki, Akiko – sequence: 6 givenname: Linda surname: Cantley fullname: Cantley, Linda – sequence: 7 givenname: Louis surname: Fazen fullname: Fazen, Louis – sequence: 8 givenname: Julian orcidid: 0000-0001-8509-0700 surname: Campillo Luna fullname: Campillo Luna, Julian – sequence: 9 givenname: Martin surname: Slade fullname: Slade, Martin – sequence: 10 givenname: Carrie A. surname: Redlich fullname: Redlich, Carrie A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35041700$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9uK2zAQhk3Z0j20b1BaQaG0F04ly5btvSiE9BRYupC0eysmspQoOFZWkkO3T19545R4WUrxhcT4m18zPzPn0UljGhlFLwkeEZqTD2vT2gbq0TaERzhhCcvyJ9EZKWkSswTTk6P7aXTu3BrjjBaMPYtOaYZTkmN8Ft1-kjtZm-1GNh5BU6HW61r_Bq9Ng4xCgFxrrVmCl2g-ns3jibmJE7TTFmrUyNaH84CDc3CHvOku0jm0mX0fox0IoRuJrHSh0hB_Hj1VUDv5oj8vop9fPv-YfIuvrr9OJ-OrWLAy8XFRpjLLKlkJRSsosoKWFQalCMkwSQTDZZ7iBauKgipKq0QCAZosclqqSi7Skl5Er_e629o43rvleDCKBAFKWCCme6IysOZbqzdg77gBze8Dxi45WK9FLXlRJFSRvBQyq9IkU1AqIKmgCwllKDAPWh_719rFJhQd7AzODESHfxq94kuz40XOMka7ct_1AtbcttJ5vtFOyLqGRpp2X3fCcpbigL55gD7eXU8tITSgG2XCu6IT5WNWlMFPyjqt0SNU-Cq50SKMltIhPkh4P0gIjJe__BJa5_h0Pvt_9vpmyL49YlcSar9ypm67yXJD8NWx038tPsx0AC73gLDGOSsVF9rfT2hoTdecYN4t0ME03i0Q7xcoJKcPkg_6_0z7Ax-aH8Q |
| CitedBy_id | crossref_primary_10_1134_S002689332206005X crossref_primary_10_3390_immuno4010007 crossref_primary_10_3390_v15071504 crossref_primary_10_1097_JOM_0000000000002617 crossref_primary_10_1371_journal_pone_0287377 crossref_primary_10_1128_spectrum_02747_22 crossref_primary_10_3389_fimmu_2023_1061255 crossref_primary_10_1021_acs_analchem_5c00666 crossref_primary_10_1007_s00216_022_04416_6 |
| Cites_doi | 10.1038/s41392-021-00481-y 10.1371/journal.pone.0251114 10.1172/jci.insight.142362 10.1016/S2666-5247(21)00025-2 10.1126/science.abd0827 10.1056/NEJMoa2029849 10.1056/NEJMc2102051 10.1016/j.jim.2014.02.013 10.1016/j.bsheal.2021.02.001 10.1016/j.jviromet.2021.114297 10.1126/scitranslmed.abi8452 10.1128/JCM.02107-20 10.1016/j.diagmicrobio.2020.115294 10.1093/cid/cir270 10.1371/journal.pone.0249499 10.1016/j.cell.2020.09.037 10.1038/s41587-020-0631-z 10.1056/NEJMc2103916 10.1038/s41586-020-2571-7 10.1038/s41596-021-00536-y 10.1038/s41467-020-18319-6 10.1016/j.vaccine.2017.10.027 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 Public Library of Science 2022 Wisnewski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 Wisnewski et al 2022 Wisnewski et al |
| Copyright_xml | – notice: COPYRIGHT 2022 Public Library of Science – notice: 2022 Wisnewski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 Wisnewski et al 2022 Wisnewski et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0262657 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection (ProQuest) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection (ProQuest) Agricultural & Environmental Science Collection (ProQuest) ProQuest Central Essentials Biological Science Collection (ProQuest) ProQuest Central Technology Collection (ProQuest) Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection (ProQuest) Environmental Science Collection (ProQuest) Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Surrogate neutralizing assay on vaccinated subjects |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2621012316 oai_doaj_org_article_8823f179ce5d425fa9fa14c3bea9cf37 PMC8765639 A689839360 35041700 10_1371_journal_pone_0262657 |
| Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
| GeographicLocations | United States United States--US Connecticut |
| GeographicLocations_xml | – name: United States – name: Connecticut – name: United States--US |
| GrantInformation_xml | – fundername: ACL HHS grantid: T03OH008607 – fundername: NIOSH CDC HHS grantid: T01 OH008607 – fundername: NIOSH CDC HHS grantid: T03 OH008607 – fundername: ; grantid: 5T03OH008607-15 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-894e55dedcf3da85839d0aff115012c609740b6d883f33d2ea1a32b739fdeb493 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 06 00:55:09 EST 2022 Wed Aug 27 01:32:26 EDT 2025 Thu Aug 21 18:16:33 EDT 2025 Thu Jul 10 22:58:31 EDT 2025 Fri Jul 25 11:29:01 EDT 2025 Tue Jun 17 21:11:15 EDT 2025 Tue Jun 10 20:30:43 EDT 2025 Fri Jun 27 05:05:22 EDT 2025 Fri Jun 27 05:12:55 EDT 2025 Thu May 22 21:23:25 EDT 2025 Mon Jul 21 05:45:41 EDT 2025 Thu Apr 24 22:58:35 EDT 2025 Tue Jul 01 01:04:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-894e55dedcf3da85839d0aff115012c609740b6d883f33d2ea1a32b739fdeb493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0001-8509-0700 0000-0003-2461-9409 0000-0002-7824-9856 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0262657 |
| PMID | 35041700 |
| PQID | 2621012316 |
| PQPubID | 1436336 |
| PageCount | e0262657 |
| ParticipantIDs | plos_journals_2621012316 doaj_primary_oai_doaj_org_article_8823f179ce5d425fa9fa14c3bea9cf37 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8765639 proquest_miscellaneous_2621267640 proquest_journals_2621012316 gale_infotracmisc_A689839360 gale_infotracacademiconefile_A689839360 gale_incontextgauss_ISR_A689839360 gale_incontextgauss_IOV_A689839360 gale_healthsolutions_A689839360 pubmed_primary_35041700 crossref_citationtrail_10_1371_journal_pone_0262657 crossref_primary_10_1371_journal_pone_0262657 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-18 |
| PublicationDateYYYYMMDD | 2022-01-18 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2022 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | N Doria-Rose (pone.0262657.ref025) 2021; 384 M Bergwerk (pone.0262657.ref001) 2021 C Graham (pone.0262657.ref008) E Burnett (pone.0262657.ref028) 2017; 35 F Amanat (pone.0262657.ref024) 2021 J Hansen (pone.0262657.ref009) 2020; 369 KT Abe (pone.0262657.ref013) 2020; 5 M Sarzotti-Kelsoe (pone.0262657.ref022) 2014; 409 J Zell (pone.0262657.ref017) 2021; 16 L Liu (pone.0262657.ref023) 2020; 584 L Piccoli (pone.0262657.ref006) 2020; 183 EJ Valcourt (pone.0262657.ref014) 2021; 99 P Chen (pone.0262657.ref011) 2020; 384 T Bradley (pone.0262657.ref016) 2021; 384 E Leuridan (pone.0262657.ref029) 2011; 53 C Fenwick (pone.0262657.ref026) 2021 A. Maxmen (pone.0262657.ref018) 2021 WN Chia (pone.0262657.ref004) 2021; 2 P Deb (pone.0262657.ref010) 2021; 3 A Krüttgen (pone.0262657.ref015) 2022; 299 A Addetia (pone.0262657.ref002) 2020; 58 P Jin (pone.0262657.ref003) 2021; 6 pone.0262657.ref019 J Yang (pone.0262657.ref007) 2020; 11 AV Wisnewski (pone.0262657.ref021) 2021; 16 P Kaaijk (pone.0262657.ref027) 2020; 221 KR Bewley (pone.0262657.ref005) 2021; 16 CW Tan (pone.0262657.ref012) 2020; 38 C Lucas (pone.0262657.ref020) 2021 |
| References_xml | – volume: 6 start-page: 48 issue: 1 year: 2021 ident: pone.0262657.ref003 article-title: Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need publication-title: Signal Transduction and Targeted Therapy doi: 10.1038/s41392-021-00481-y – volume: 16 start-page: e0251114 issue: 8 year: 2021 ident: pone.0262657.ref017 article-title: Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel publication-title: PLoS One doi: 10.1371/journal.pone.0251114 – volume: 5 start-page: e142362 issue: 19 year: 2020 ident: pone.0262657.ref013 article-title: A simple protein-based surrogate neutralization assay for SARS-CoV-2 publication-title: JCI Insight doi: 10.1172/jci.insight.142362 – volume: 2 start-page: e240 issue: 6 year: 2021 ident: pone.0262657.ref004 article-title: Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study publication-title: The Lancet Microbe doi: 10.1016/S2666-5247(21)00025-2 – volume: 369 start-page: 1010 issue: 6506 year: 2020 ident: pone.0262657.ref009 article-title: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail publication-title: Science doi: 10.1126/science.abd0827 – volume: 384 start-page: 229 issue: 3 year: 2020 ident: pone.0262657.ref011 article-title: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2029849 – volume: 384 start-page: 1959 issue: 20 year: 2021 ident: pone.0262657.ref016 article-title: Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine publication-title: New England Journal of Medicine doi: 10.1056/NEJMc2102051 – year: 2021 ident: pone.0262657.ref018 article-title: COVID boosters for wealthy nations spark outrage publication-title: Nature – volume: 409 start-page: 147 year: 2014 ident: pone.0262657.ref022 article-title: Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells publication-title: J Immunol Methods doi: 10.1016/j.jim.2014.02.013 – volume: 3 start-page: 87 issue: 2 year: 2021 ident: pone.0262657.ref010 article-title: An update to monoclonal antibody as therapeutic option against COVID-19 publication-title: Biosafety and Health doi: 10.1016/j.bsheal.2021.02.001 – volume: 299 start-page: 114297 year: 2022 ident: pone.0262657.ref015 article-title: Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273 publication-title: J Virol Methods doi: 10.1016/j.jviromet.2021.114297 – start-page: eabi8452 year: 2021 ident: pone.0262657.ref026 article-title: A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma publication-title: Science Translational Medicine doi: 10.1126/scitranslmed.abi8452 – volume: 58 issue: 11 year: 2020 ident: pone.0262657.ref002 article-title: Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate publication-title: J Clin Microbiol doi: 10.1128/JCM.02107-20 – year: 2021 ident: pone.0262657.ref020 article-title: Delayed production of neutralizing antibodies correlates with fatal COVID-19 publication-title: Nature Medicine – volume: 99 start-page: 115294 issue: 4 year: 2021 ident: pone.0262657.ref014 article-title: Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) publication-title: Diagnostic Microbiology and Infectious Disease doi: 10.1016/j.diagmicrobio.2020.115294 – volume: 53 start-page: 68 issue: 1 year: 2011 ident: pone.0262657.ref029 article-title: Hepatitis B and the Need for a Booster Dose publication-title: Clinical Infectious Diseases doi: 10.1093/cid/cir270 – year: 2021 ident: pone.0262657.ref024 article-title: The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD publication-title: medRxiv – volume: 16 start-page: e0249499 issue: 6 year: 2021 ident: pone.0262657.ref021 article-title: Human IgG and IgA responses to COVID-19 mRNA vaccines publication-title: PLoS One doi: 10.1371/journal.pone.0249499 – ident: pone.0262657.ref008 article-title: Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant publication-title: Immunity – ident: pone.0262657.ref019 – volume: 183 start-page: 1024 issue: 4 year: 2020 ident: pone.0262657.ref006 article-title: Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology publication-title: Cell doi: 10.1016/j.cell.2020.09.037 – year: 2021 ident: pone.0262657.ref001 article-title: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers publication-title: New England Journal of Medicine – volume: 38 start-page: 1073 issue: 9 year: 2020 ident: pone.0262657.ref012 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction publication-title: Nature Biotechnology doi: 10.1038/s41587-020-0631-z – volume: 384 start-page: 2259 issue: 23 year: 2021 ident: pone.0262657.ref025 article-title: Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 publication-title: New England Journal of Medicine doi: 10.1056/NEJMc2103916 – volume: 584 start-page: 450 issue: 7821 year: 2020 ident: pone.0262657.ref023 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 16 start-page: 3114 issue: 6 year: 2021 ident: pone.0262657.ref005 article-title: Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays publication-title: Nature Protocols doi: 10.1038/s41596-021-00536-y – volume: 11 start-page: 4541 issue: 1 year: 2020 ident: pone.0262657.ref007 article-title: Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor publication-title: Nature Communications doi: 10.1038/s41467-020-18319-6 – volume: 221 start-page: 902 issue: 6 year: 2020 ident: pone.0262657.ref027 article-title: A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults publication-title: J Infect Dis – volume: 35 start-page: 7198 issue: 51 year: 2017 ident: pone.0262657.ref028 article-title: Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality publication-title: Vaccine doi: 10.1016/j.vaccine.2017.10.027 |
| SSID | ssj0053866 |
| Score | 2.4284096 |
| Snippet | Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction... Background Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque... BackgroundTests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque... Background Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0262657 |
| SubjectTerms | ACE2 Angiotensin Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - chemistry Angiotensin-Converting Enzyme 2 - immunology Antibodies Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Biology and life sciences Biosafety Competition Consent Coronaviruses Correlation COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Enzyme-Linked Immunosorbent Assay Enzymes Evaluation Female Health aspects Humans Immune response Immune system Immunity Immunoassays Infections Internal medicine Male Medicine Medicine and Health Sciences mRNA mRNA vaccines mRNA Vaccines - administration & dosage mRNA Vaccines - immunology Neutralization Neutralizing Peptidyl-dipeptidase A Phlebotomy Proteins Receptors Regression analysis Research and Analysis Methods SARS-CoV-2 - immunology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike protein Testing Vaccination Vaccines Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology Viral diseases |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyqsLLRiEBBzSxnHixMeloipIFGmXVr1Fjh-AtCTbzQaJf89M7I02qFI5cIviL1EyM54ZJzOfCXktpGNp7lykuBVRaqVBDkgRMaYhYogKgiY2OH8-F2cX6aer7Gpnqy-sCfP0wF5wx5ABcgdWo21mwL6ckk6xVPPKKqkd7_vIIeZtF1PeB8MsFiI0yvGcHQe9HK2a2h7BqiMRGI52AlHP1z945clq2bQ3pZx_V07uhKLT--ReyCHpzD_7Hrlj6wdkL8zSlr4NVNLvHpLrnZogqmpDwcyWofOSNo4q2nbrdYOf0uhiNl9EJ81llFAs_F3S2nb9Z5AAhyxb_aabBg_APdKf8_MZ_aU0_pmna19qa9tH5OL0w9eTsyhsshBpIZNNVMjUZpmBV3LcqCKDhMnEyjnMFFmiRQwLjrgSpii449wkVjHFkyrn0hlbpZI_JpMaxLpPqFYycQa0kvAqzfO8ElzFTMMaM1ecaT4lfCvxUgcGctwIY1n2v9VyWIl4AZaopzLoaUqi4aqVZ-C4Bf8elTlgkT-7PwFWVQarKm-zqil5gaZQ-mbUwQuUM1FIkBAX8ZS86hHIoVFjkc431bVt-fHL5T-AFvMR6E0AuQbEoVVojIB3Qm6uEfJghARPoEfD-2i4W6m0JQgE6ds4E3Dl1phvHn45DONNsfCutk3nMYnIRQp3f-Jtf5Asz-IU6R2nJB_NipHoxyP1j-89hTnE4Axy46f_Q1fPyN0Ee1JiFrHigEw2684eQqa4qZ73TuEP-F9o3g priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegSIgXxMbHCgMMQgIevMV24iRPqExMA2lDatnUt8hx7IFUkq5pkPjvuUvc0KAJeIvii5OcfV_23c-EvFKp42HsHNPSKhbatEAMSMU4N2AxVA5GEwucT8_UyXn4aR7N_YJb7dMqNzqxVdRFZXCN_FAogVBUkqt3yyuGp0bh7qo_QuMmuYXQZZjSFc_7gAtkWSlfLidjfuhH52BZlfYAYg-h0ChtmaMWtb_XzaPloqqvczz_zJ_cMkjH98hd70nSSTf0O-SGLXfJ7VO_V75LdrzY1vSNx5Z-e59cbSUJUV0WFObdwpdi0spRTetmtapwbY3OJtMZO6oumKCYCbygpW3adRFPDm63_knXFV6AvqTfp2cT-kMbfD1ddbm3tn5Azo8_fDk6Yf7UBWZUKtYsSUMbRQX8nZOFTiLwoIpAO4euIxdGBRCBBLkqkkQ6KQthNddS5LFMXWHzMJUPyagEDu8RanQqXJEaJ2QexnGcK6kDbiDojLXkRo6J3DA_Mx6SHE_GWGTtPlsMoUnHywyHLPNDNiasf2rZQXL8g_49jmtPi4Da7Y1qdZl5-cwg0JAOlJOxUQFqzOnUaR4amVsN3y-hk-c4K7KuOrVXC9lEJSlwSKpgTF62FAiqUWLWzqVu6jr7-PniP4hm0wHRa0_kKmCH0b5SAv4JwboGlPsDSlANZtC8h3N4w5U6-y1E8ORmXl_f_KJvxk4xE6-0VdPRCBWrEHp_1IlBz1kZBSHiPY5JPBCQAeuHLeW3ry2mORjlCJzlx3__rCfkjsDyk4AznuyT0XrV2KfgFK7zZ63k_wKTgGKG priority: 102 providerName: ProQuest |
| Title | Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35041700 https://www.proquest.com/docview/2621012316 https://www.proquest.com/docview/2621267640 https://pubmed.ncbi.nlm.nih.gov/PMC8765639 https://doaj.org/article/8823f179ce5d425fa9fa14c3bea9cf37 http://dx.doi.org/10.1371/journal.pone.0262657 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0NqHhPaCGF8rjGIQEvCQKo4TO3lAqJs2BtIKaunUt8hx7IFUkq1pEXvht3OXuNGChkC8WFF8tpLzfdp3Z0JeiMSyUFrrKW6EF5okxxqQwmNMg8YQGShNTHA-HYmTafhhFs02yPrOVofA6kbXDu-Tmi7mgx-XV2-B4d_UtzZIth40uCgLMwCfIhCR3CTboJsksupp2J4rAHcL4RLo_jRyh9zikR9i3bqOrqpL-reCe-tiXlY3WaW_B1de01bHd8htZ2bSYUMXu2TDFHfJrmPkir5y1aZf3yOX18KGqCpyCpQ4d8mZtLRU0Wq1WJS420Ynw_HEOyzPvIBibPCcFmZV75Q4cDDE1RVdlvgAEpR-G4-G9LvSeHhPF000rqnuk-nx0efDE8_dw-BpkQRLL05CE0U5_JLluYojsKlyX1mLxiQLtPDBJ_Ezkccxt5zngVFM8SCTPLG5ycKEPyBbBWB4j1CtksDmibYBz0IpZSa48pkGN1QqzjTvEb7GeKpdkXK8K2Oe1idvEpyVBoEpLlnqlqxHvHbURVOk4y_wB7iYLSyW2K5flIvz1HFsCq4HtyCutIlyEGxWJVaxUPPMKPh-DpM8RVJIm3zVVlCkQxEngCEu_B55XkNgmY0C43jO1aqq0vcfz_4BaDLuAL10QLYEdGjlcifgn7B8VwdyvwMJwkJ3uveQcNdYqVJACFZ440zAyDUx39z9rO3GSTE2rzDlqoEJhBQhzP6wof0Ws2tO6hHZ4YoO6rs9xdcvdZVzUNMRmM-P_nvkY7ITYK6KzzwW75Ot5WJlnoAFucz6ZFPOJLTxIcP2-F2fbB8cjT6N-_WeTL8WGtj-PPoFjXh48A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIQEviI0_KwxmEAh4yJbYidM8IFQGU8vWIrXb1LfMceyBVJKuaUH7UnxG7hI3NGgCXvZW1Rc3vTv_7s6-OxPyQkTG80NjHMm1cHwdpdgDUjiep8BiiASMJhY49weie-J_GgfjNfJzWQuDaZVLTCyBOs0V7pHvMcGwFRX3xLvphYO3RuHp6vIKjUotDvXlDwjZire9DyDfl4wdfDze7zr2VgFHiYjNnXbk6yBIdaoMT2U7AA8hdaUx6Bp5TAkXPGw3EWm7zQ3nKdPSk5wlIY9MqhMfmy8B5N8Aw-viigrHdYAH2CGELc_jobdntWF3mmd6F2IdJtAIrpi_8paA2hasTyd5cZWj-2e-5ooBPLhL7ljPlXYqVdsgazrbJDf79mx-k2xYmCjoa9vL-s09crGSlERlllLQ84kt_aS5oZIWi9ksx708OuoMR85-fuowipnHE5rpRbkPY8nBzZeXdJ7jB8Bn-m046NDvUuHP01mV66uL--TkWuTxgKxnwOEtQpWMmEkjZRhP_DAME8Gl6ykIckPJPcVbhC-ZHyvbAh1v4pjE5bleCKFQxcsYRRZbkbWIUz81rVqA_IP-Pcq1psUG3uUX-ew8tngQQ2DDDYCh0kEKsGlkZKTnK55oCe_PYZId1Iq4qoatYSjuiHYEHOLCbZHnJQU28cgwS-hcLooi7n0-_Q-i0bBB9MoSmRzYoaStzID_hM3BGpTbDUqAItUY3kIdXnKliH8vWnhyqddXDz-rh3FSzPzLdL6oaJgIhQ-zP6yWQc1ZHrg-9pdskbCxQBqsb45kX7-UPdTBCQjAOX_099faIbe6x_2j-Kg3OHxMbjMsfXE9x2tvk_X5bKGfgEM6T56WKEDJ2XXDzi_OtZ-d |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIU28IDb-rDCYQSDgIVtsJ07zgFDZqFbGCtrYtLfMceyBVJKuaUH7anw67hI3NGgCXvZW1Rc3vTv_7s6-OxPyTMaWBZG1nhJGeoGJM-wBKT3GNFgMmYLRxALng6HcOw7en4anS-TnvBYG0yrnmFgBdVZo3CPf5pJjKyrB5LZ1aRGfdvtvxhce3iCFJ63z6zRqFdk3lz8gfCtfD3ZB1s8577_7vLPnuRsGPC1jPvW6cWDCMDOZtiJT3RC8hcxX1qKbxLiWPnjbfiqzbldYITJuFFOCp5GIbWbSABsxAfzfiETIcI1Fp02wBzgipSvVExHbdpqxNS5yswVxD5doEBdMYXVjQGMXlsejorzK6f0zd3PBGPZvk1vOi6W9Wu1WyZLJ18jKgTunXyOrDjJK-tL1tX51h1wsJChRlWcUdH7kykBpYami5WwyKXBfjx71Do-8neLE4xSzkEc0N7NqT8aRg8uvLum0wA-A1fTb4bBHvyuNP08ndd6vKe-S42uRxz2ynAOH1wnVKuY2i7XlIg2iKEqlUD7TEPBGSjAtOkTMmZ9o1w4db-UYJdUZXwRhUc3LBEWWOJF1iNc8Na7bgfyD_i3KtaHFZt7VF8XkPHHYkECQIywAozZhBhBqVWwVC7RIjYL3FzDJJmpFUlfGNpCU9GQ3Bg4J6XfI04oCG3rkuDTO1awsk8HHk_8gOjpsEb1wRLYAdmjlqjTgP2GjsBblRosSYEm3htdRh-dcKZPfCxienOv11cNPmmGcFLMAc1PMahouIxnA7PfrZdBwVoR-gL0mOyRqLZAW69sj-dcvVT91cAhCcNQf_P21NskKAE7yYTDcf0hucqyC8ZnHuhtkeTqZmUfgm07TxxUIUHJ23ajzC0I_o9M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+utilization+of+a+surrogate+SARS-CoV-2+viral+neutralization+assay+to+assess+mRNA+vaccine+responses&rft.jtitle=PloS+one&rft.au=Wisnewski%2C+Adam+V.&rft.au=Liu%2C+Jian&rft.au=Lucas%2C+Carolina&rft.au=Klein%2C+Jon&rft.date=2022-01-18&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1371%2Fjournal.pone.0262657&rft_id=info%3Apmid%2F35041700&rft.externalDocID=PMC8765639 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |